Cargando…

Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis

BACKGROUND: In Israel, an average of 37 children are born each year with sepsis and another four with meningitis as a result of Group B Streptococcal (GBS) disease. Israel currently only screens mothers with defined risk factors (around 15% of all pregnancies) in order to identify candidates for Int...

Descripción completa

Detalles Bibliográficos
Autores principales: Ginsberg, Gary M, Eidelman, Arthur I, Shinwell, Eric, Anis, Emilia, Peyser, Reuven, Lotan, Yoram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585784/
https://www.ncbi.nlm.nih.gov/pubmed/23425020
http://dx.doi.org/10.1186/2045-4015-2-6
_version_ 1782261205742649344
author Ginsberg, Gary M
Eidelman, Arthur I
Shinwell, Eric
Anis, Emilia
Peyser, Reuven
Lotan, Yoram
author_facet Ginsberg, Gary M
Eidelman, Arthur I
Shinwell, Eric
Anis, Emilia
Peyser, Reuven
Lotan, Yoram
author_sort Ginsberg, Gary M
collection PubMed
description BACKGROUND: In Israel, an average of 37 children are born each year with sepsis and another four with meningitis as a result of Group B Streptococcal (GBS) disease. Israel currently only screens mothers with defined risk factors (around 15% of all pregnancies) in order to identify candidates for Intrapartum Antiobiotic Prophyhlaxis (IAP) of GBS. This paper presents a cost-utility analysis of implementing an alternative strategy, which would expand the current protocol to one aiming to screen all pregnant women at 35–37 weeks gestation based on taking a vaginal culture for GBS. METHODS: A spreadsheet model was built incorporating technical, epidemiological, health service costs, demographic and economic data based primarily on Israeli sources. RESULTS: The intervention of universal screening (compared with the current scenario) would increase screening costs from 580,000 NIS to 3,278,000 million NIS. In addition, the intervention would also increase penicillin costs from 39,000 NIS to 221,000 NIS. Current culture screening of approximately 15% of mothers-to-be with high risk factors resulted in 42 GBS births in 2008-9 (0.253/1000 births). Expanding culture screening to 85% of mothers-to-be, will decrease the number of GBS births to 17.3 (0.104/1000 births). The initial 2.9 million NIS incremental intervention costs are offset by decreased treatment costs of 1.9 million NIS and work productivity gains of 811,000 NIS as a result of a decrease in neurological sequelae from GBS caused meningitis. Thus the resultant net cost of the intervention is only around 134,000 NIS. Culture based screening will reduce the burden of disease by 12.6 discounted Quality Adjusted Life Years (QALYS), giving a very cost effective baseline incremental cost per QALY (cf. risk factor screening) of 10,641 NIS per QALY. The data was very sensitive to rates of anaphylactic shock and changes in the percentage of meningitis cases that had associated long term-sequelae. CONCLUSION: It is recommended that Israel adopt universal culture-based GBS screening.
format Online
Article
Text
id pubmed-3585784
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35857842013-03-12 Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis Ginsberg, Gary M Eidelman, Arthur I Shinwell, Eric Anis, Emilia Peyser, Reuven Lotan, Yoram Isr J Health Policy Res Original Research Article BACKGROUND: In Israel, an average of 37 children are born each year with sepsis and another four with meningitis as a result of Group B Streptococcal (GBS) disease. Israel currently only screens mothers with defined risk factors (around 15% of all pregnancies) in order to identify candidates for Intrapartum Antiobiotic Prophyhlaxis (IAP) of GBS. This paper presents a cost-utility analysis of implementing an alternative strategy, which would expand the current protocol to one aiming to screen all pregnant women at 35–37 weeks gestation based on taking a vaginal culture for GBS. METHODS: A spreadsheet model was built incorporating technical, epidemiological, health service costs, demographic and economic data based primarily on Israeli sources. RESULTS: The intervention of universal screening (compared with the current scenario) would increase screening costs from 580,000 NIS to 3,278,000 million NIS. In addition, the intervention would also increase penicillin costs from 39,000 NIS to 221,000 NIS. Current culture screening of approximately 15% of mothers-to-be with high risk factors resulted in 42 GBS births in 2008-9 (0.253/1000 births). Expanding culture screening to 85% of mothers-to-be, will decrease the number of GBS births to 17.3 (0.104/1000 births). The initial 2.9 million NIS incremental intervention costs are offset by decreased treatment costs of 1.9 million NIS and work productivity gains of 811,000 NIS as a result of a decrease in neurological sequelae from GBS caused meningitis. Thus the resultant net cost of the intervention is only around 134,000 NIS. Culture based screening will reduce the burden of disease by 12.6 discounted Quality Adjusted Life Years (QALYS), giving a very cost effective baseline incremental cost per QALY (cf. risk factor screening) of 10,641 NIS per QALY. The data was very sensitive to rates of anaphylactic shock and changes in the percentage of meningitis cases that had associated long term-sequelae. CONCLUSION: It is recommended that Israel adopt universal culture-based GBS screening. BioMed Central 2013-02-20 /pmc/articles/PMC3585784/ /pubmed/23425020 http://dx.doi.org/10.1186/2045-4015-2-6 Text en Copyright ©2013 Ginsberg et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Ginsberg, Gary M
Eidelman, Arthur I
Shinwell, Eric
Anis, Emilia
Peyser, Reuven
Lotan, Yoram
Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
title Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
title_full Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
title_fullStr Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
title_full_unstemmed Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
title_short Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
title_sort should israel screen all mothers-to-be to prevent early-onset of neonatal group b streptococcal disease? a cost-utility analysis
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585784/
https://www.ncbi.nlm.nih.gov/pubmed/23425020
http://dx.doi.org/10.1186/2045-4015-2-6
work_keys_str_mv AT ginsberggarym shouldisraelscreenallmotherstobetopreventearlyonsetofneonatalgroupbstreptococcaldiseaseacostutilityanalysis
AT eidelmanarthuri shouldisraelscreenallmotherstobetopreventearlyonsetofneonatalgroupbstreptococcaldiseaseacostutilityanalysis
AT shinwelleric shouldisraelscreenallmotherstobetopreventearlyonsetofneonatalgroupbstreptococcaldiseaseacostutilityanalysis
AT anisemilia shouldisraelscreenallmotherstobetopreventearlyonsetofneonatalgroupbstreptococcaldiseaseacostutilityanalysis
AT peyserreuven shouldisraelscreenallmotherstobetopreventearlyonsetofneonatalgroupbstreptococcaldiseaseacostutilityanalysis
AT lotanyoram shouldisraelscreenallmotherstobetopreventearlyonsetofneonatalgroupbstreptococcaldiseaseacostutilityanalysis